Oncology Institute (TOIIW) Cash & Current Investments (2019 - 2026)

Oncology Institute has reported Cash & Current Investments for 8 years, with the latest figure at $30.3 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments fell 23.8% year-over-year to $30.3 million; the trailing twelve-month figure through Mar 2026 stood at $30.3 million (down 23.8% YoY), and the FY2025 full-year result was $33.6 million, down 32.42% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $30.3 million, down from $33.6 million in the prior quarter.
• The five-year high for Cash & Current Investments was $95.5 million in Q1 2022, with the low at $27.7 million in Q3 2025.
• Historically, Cash & Current Investments has averaged $56.5 million across 5 years, with a median of $49.7 million in 2024.
• Annual changes were most pronounced in 2022 — Cash & Current Investments surged 685.46% — and 2024, when it tumbled 45.77%.
• Oncology Institute's Cash & Current Investments stood at $73.8 million in 2022, then increased by 12.26% to $82.9 million in 2023, then plunged by 40.05% to $49.7 million in 2024, then slumped by 32.42% to $33.6 million in 2025, then dropped by 9.79% to $30.3 million in 2026.
• The last three Cash & Current Investments figures came in at $30.3 million (Q1 2026), $33.6 million (Q4 2025), and $27.7 million (Q3 2025), per Business Quant data.